NCT01995669 2025-06-24Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaM.D. Anderson Cancer CenterPhase 1/2 Completed66 enrolled 13 charts
NCT04578600 2025-04-24CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaUniversity of California, DavisPhase 1 Completed8 enrolled
NCT03010358 2023-08-08Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaOHSU Knight Cancer InstitutePhase 1/2 Completed24 enrolled 16 charts
NCT03374137 2023-01-12Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaHoffmann-La RocheCompleted55 enrolled
NCT01680991 2016-04-25A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant DiseaseHoffmann-La RochePhase 1 Completed48 enrolled 27 charts